<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22166044</article-id><article-id pub-id-type="pmc">3267706</article-id><article-id pub-id-type="publisher-id">1471-2407-11-517</article-id><article-id pub-id-type="doi">10.1186/1471-2407-11-517</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Galvão</surname><given-names>Daniel A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>d.galvao@ecu.edu.au</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Taaffe</surname><given-names>Dennis R</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Dennis.Taaffe@newcastle.edu.au</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Cormie</surname><given-names>Prue</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>p.cormie@ecu.edu.au</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Spry</surname><given-names>Nigel</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>Nigel.Spry@health.wa.gov.au</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Chambers</surname><given-names>Suzanne K</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>suzanne.chambers@griffith.edu.au</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Peddle-McIntyre</surname><given-names>Carolyn</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>c.mcintyre@ecu.edu.au</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Baker</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>michael.baker@ecu.edu.au</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Denham</surname><given-names>James</given-names></name><xref ref-type="aff" rid="I7">7</xref><xref ref-type="aff" rid="I8">8</xref><email>Jim.Denham@newcastle.edu.au</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Joseph</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>David.Joseph@health.wa.gov.au</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Groom</surname><given-names>Geoff</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>Geoffrey.Groom@perthradclinic.com.au</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Newton</surname><given-names>Robert U</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>r.newton@ecu.edu.au</email></contrib></contrib-group><aff id="I1"><label>1</label>Edith Cowan University Health and Wellness Institute and School of Exercise and Health Sciences, Edith Cowan University, Joondalup, Australia</aff><aff id="I2"><label>2</label>School of Environmental and Life Sciences, University of Newcastle, Ourimbah, Australia</aff><aff id="I3"><label>3</label>Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Australia</aff><aff id="I4"><label>4</label>Faculty of Medicine, University of Western Australia, Nedlands, Australia</aff><aff id="I5"><label>5</label>Griffith Health Institute, Griffith University, Gold Coast, Australia</aff><aff id="I6"><label>6</label>Viertel Centre for Research in Cancer Control, Cancer Council Queensland, Brisbane, Australia</aff><aff id="I7"><label>7</label>School of Medicine and Public Health, University of Newcastle, Newcastle, Australia</aff><aff id="I8"><label>8</label>Newcastle Mater Hospital, Newcastle, Australia</aff><aff id="I9"><label>9</label>Perth Radiological Clinic, Joondalup Health Campus, Joondalup, Australia</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>13</day><month>12</month><year>2011</year></pub-date><volume>11</volume><fpage>517</fpage><lpage>517</lpage><history><date date-type="received"><day>22</day><month>11</month><year>2011</year></date><date date-type="accepted"><day>13</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>Copyright ©2011 Galvão et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Galvão et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/11/517"></self-uri><abstract><sec><title><offsets xml_i="5674" xml_f="5684" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5695" xml_f="6350" txt_i="22" txt_f="677">The presence of bone metastases has excluded participation of prostate cancer patients in exercise intervention studies to date and is also a relative contraindication to supervised exercise in the community setting because of concerns of fragility fracture. However, this group of patients often have developed significant muscle atrophy and functional impairments from prior and continuing androgen deprivation that is exacerbated by subsequent and more intensive interventions such as chemotherapy. The aim of this study is to determine the efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases.</offsets></p></sec><sec><title><offsets xml_i="6372" xml_f="6386" txt_i="679" txt_f="693">Methods/Design</offsets></title><p><offsets xml_i="6397" xml_f="7001" txt_i="694" txt_f="1298">Multi-site randomized controlled trial in Western Australia and New South Wales to examine the efficacy and safety of a modular multi-modal physical exercise program in 90 prostate cancer survivors with bone metastases. Participants will be randomized to (1) modular multi-modal exercise intervention group or (2) usual medical care group. The modular multi-modal exercise group will receive a 3-month supervised exercise program based on bone lesion location/extent. Measurements for primary and secondary endpoints will take place at baseline, 3 months (end of the intervention) and 6 months follow-up.</offsets></p></sec><sec><title><offsets xml_i="7023" xml_f="7033" txt_i="1300" txt_f="1310">Discussion</offsets></title><p><offsets xml_i="7044" xml_f="7714" txt_i="1311" txt_f="1981">Delaying or preventing skeletal complication and improving physical function for men with bone metastases would provide clinically meaningful benefits to patients. However, exercise programs must be designed and executed with careful consideration of the skeletal complications associated with bone metastatic disease and cumulative toxicities from androgen deprivation such as osteoporosis and increased risk of fractures. The results from this study will form the basis for the development of a specific exercise prescription in this patient group in order to alleviate disease burden, counteract the adverse treatment related side-effects and enhance quality of life.</offsets></p></sec><sec><title><offsets xml_i="7736" xml_f="7754" txt_i="1983" txt_f="2001">Trial Registration</offsets></title><p><offsets xml_i="7765" xml_f="7772" txt_i="2002" txt_f="2009">ACTRN: </offsets><ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au/ACTRN12611001158954.aspx"><offsets xml_i="7865" xml_f="7884" txt_i="2009" txt_f="2028">ACTRN12611001158954</offsets></ext-link></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="7957" xml_f="7967" txt_i="2037" txt_f="2047">Background</offsets></title><p><offsets xml_i="7978" xml_f="8063" txt_i="2048" txt_f="2133">Metastases to bone occurs in approximately 80% of men with advanced prostate cancer [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8094" xml_f="8095" txt_i="2133" txt_f="2134">1</offsets></xref><offsets xml_i="8102" xml_f="8365" txt_i="2134" txt_f="2397">] and the majority of these patients are at risk of developing pathological fractures, hypercalcemia, bone marrow suppression and nerve compressions or spinal cord compressions that result in significant morbidity, limited function and decreased quality of life [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="8396" xml_f="8397" txt_i="2397" txt_f="2398">2</offsets></xref><offsets xml_i="8404" xml_f="8405" txt_i="2398" txt_f="2399">-</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="8436" xml_f="8437" txt_i="2399" txt_f="2400">4</offsets></xref><offsets xml_i="8444" xml_f="8593" txt_i="2400" txt_f="2549">]. The clinical course of metastatic bone disease in prostate cancer survivors is relatively long, with a 5-year survival rate of approximately 30% [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="8624" xml_f="8625" txt_i="2549" txt_f="2550">5</offsets></xref><offsets xml_i="8632" xml_f="8749" txt_i="2550" txt_f="2667">]. Prostate cancer causes predominately sclerotic lesions and commonly metastasize to the pelvis and axial skeleton [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="8780" xml_f="8781" txt_i="2667" txt_f="2668">6</offsets></xref><offsets xml_i="8788" xml_f="8994" txt_i="2668" txt_f="2874">]. Therefore, patients with bone metastases experience considerable morbidity resulting from skeletal complications and fatigue secondary to chemotherapy for those with castrate-resistance prostate cancer [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="9025" xml_f="9026" txt_i="2874" txt_f="2875">3</offsets></xref><offsets xml_i="9033" xml_f="9034" txt_i="2875" txt_f="2876">,</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="9065" xml_f="9066" txt_i="2876" txt_f="2877">7</offsets></xref><offsets xml_i="9073" xml_f="9297" txt_i="2877" txt_f="3101">]. Delaying or preventing skeletal complication, improving physical function and increasing levels of physical activity in prostate cancer patients with bone metastases can provide clinically meaningful benefits to patients.</offsets></p><p><offsets xml_i="9304" xml_f="9519" txt_i="3102" txt_f="3317">Long-term androgen deprivation therapy (ADT) remains the first-line treatment for advanced metastatic prostate cancer, however it acts by inducing severe hypogonadism causing a number of cumulative adverse effects [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="9550" xml_f="9551" txt_i="3317" txt_f="3318">8</offsets></xref><offsets xml_i="9558" xml_f="9559" txt_i="3318" txt_f="3319">,</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="9590" xml_f="9591" txt_i="3319" txt_f="3320">9</offsets></xref><offsets xml_i="9598" xml_f="9735" txt_i="3320" txt_f="3457">]. Some of these physical side effects include reduction of bone and muscle mass, increased fat mass and loss of neuromuscular strength [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="9766" xml_f="9767" txt_i="3457" txt_f="3458">8</offsets></xref><offsets xml_i="9774" xml_f="9775" txt_i="3458" txt_f="3459">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="9807" xml_f="9809" txt_i="3459" txt_f="3461">10</offsets></xref><offsets xml_i="9816" xml_f="9991" txt_i="3461" txt_f="3636">]. We have shown that a 9-month exposure to ADT led to significant reductions in hip (1.5%), spine (3.9%), whole body (2.4%) and upper limb (1.3%) bone mineral density (BMD) [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="10023" xml_f="10025" txt_i="3636" txt_f="3638">11</offsets></xref><offsets xml_i="10032" xml_f="10236" txt_i="3638" txt_f="3842">]. We have also reported that men on ADT had significantly reduced upper- and lower-body muscle strength and impaired overall functional performance and balance compared to healthy aged-matched controls [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="10268" xml_f="10270" txt_i="3842" txt_f="3844">12</offsets></xref><offsets xml_i="10277" xml_f="10466" txt_i="3844" txt_f="4033">]. Notably, ADT has been associated with increased fracture risks and more importantly this risk increases with the number of doses of gonadotropin-releasing hormone agonist administrated [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="10497" xml_f="10498" txt_i="4033" txt_f="4034">8</offsets></xref><offsets xml_i="10505" xml_f="10902" txt_i="4034" txt_f="4431">]. These observations raise a major concern for men receiving long-term ADT for advanced prostate cancer, with reduced muscle strength placing prostate cancer patients at higher risk of falling particularly when combined with ADT induced reductions in bone strength, all of the sequelae of falls and fracture. This is a major concern as fractures cause significant morbidity and mortality in men [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="10934" xml_f="10936" txt_i="4431" txt_f="4433">13</offsets></xref><offsets xml_i="10943" xml_f="11043" txt_i="4433" txt_f="4533">] and has been correlated with decreased survival in prostate cancer patients with bone metastases [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="11075" xml_f="11077" txt_i="4533" txt_f="4535">14</offsets></xref><offsets xml_i="11084" xml_f="11086" txt_i="4535" txt_f="4537">].</offsets></p><p><offsets xml_i="11093" xml_f="11335" txt_i="4538" txt_f="4780">Apart from previous ADT, men with bone metastases and castrate-resistant prostate cancer would commonly receive chemotherapy given the results of initial phase III trials indicating modest survival benefit for those with symptomatic disease [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="11367" xml_f="11369" txt_i="4780" txt_f="4782">15</offsets></xref><offsets xml_i="11376" xml_f="11377" txt_i="4782" txt_f="4783">,</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="11409" xml_f="11411" txt_i="4783" txt_f="4785">16</offsets></xref><offsets xml_i="11418" xml_f="11536" txt_i="4785" txt_f="4903">]. A number of well-established adverse effects including nausea and severe fatigue are associated with chemotherapy [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="11568" xml_f="11570" txt_i="4903" txt_f="4905">15</offsets></xref><offsets xml_i="11577" xml_f="11774" txt_i="4905" txt_f="5102">]. Therefore, prostate cancer survivors with bone metastases suffer not only from the treatment-related side effects common to survivors with localised disease, but also from significant physical [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="11806" xml_f="11808" txt_i="5102" txt_f="5104">17</offsets></xref><offsets xml_i="11815" xml_f="11836" txt_i="5104" txt_f="5125">] and psychological [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="11868" xml_f="11870" txt_i="5125" txt_f="5127">18</offsets></xref><offsets xml_i="11877" xml_f="11878" txt_i="5127" txt_f="5128">,</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="11910" xml_f="11912" txt_i="5128" txt_f="5130">19</offsets></xref><offsets xml_i="11919" xml_f="11986" txt_i="5130" txt_f="5197">] issues associated with bone metastatic disease and its treatment.</offsets></p><p><offsets xml_i="11993" xml_f="12166" txt_i="5198" txt_f="5371">Clinical trials investigating the efficacy of exercise in prostate cancer survivors including our recent randomized controlled trial excluded those who had bone metastases [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="12198" xml_f="12200" txt_i="5371" txt_f="5373">20</offsets></xref><offsets xml_i="12207" xml_f="12208" txt_i="5373" txt_f="5374">-</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="12240" xml_f="12242" txt_i="5374" txt_f="5376">24</offsets></xref><offsets xml_i="12249" xml_f="12286" txt_i="5376" txt_f="5413">], or bone lesions deemed 'unstable'[</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="12318" xml_f="12320" txt_i="5413" txt_f="5415">25</offsets></xref><offsets xml_i="12327" xml_f="12497" txt_i="5415" txt_f="5585">] due to the potential increased risk of skeletal fractures. Nevertheless, recent guidelines on Exercise for Cancer Survivors by the American College of Sports Medicine [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="12529" xml_f="12531" txt_i="5585" txt_f="5587">26</offsets></xref><offsets xml_i="12538" xml_f="13382" txt_i="5587" txt_f="6431">] suggest that cancer survivors including those with bone metastases should "avoid inactivity" given the potential benefits of physical activity even for this group of cancer patients with advanced disease. However, it remains to be determined if exercise can be tolerated by patients with bone metastases given the absence of clinical data on exercise feasibility and efficacy in patients with bone metastases. This situation is highly detrimental since patients with bone metastases are reducing their physical activity levels for fear of bone fracture and clinicians are reluctant to refer patients with bone metastases for physical exercise programs. Such a strategy can only result in greater fatigue, reduced function and further declining muscle and skeletal integrity, greater risk of other chronic disease and reduced quality of life [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="13413" xml_f="13414" txt_i="6431" txt_f="6432">3</offsets></xref><offsets xml_i="13421" xml_f="13422" txt_i="6432" txt_f="6433">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="13453" xml_f="13454" txt_i="6433" txt_f="6434">4</offsets></xref><offsets xml_i="13461" xml_f="14049" txt_i="6434" txt_f="7022">]. This project is unique as it tests the implementation of a modular multi-modal exercise program (M3EP) taking into consideration location/extent of bone metastases lesions as a strategy to maintain or enhance physical function in this group of patients with advanced prostate cancer. Further, the outcomes from this trial may provide novel data that could be translated to other cancer patients with bone metastases. This is the first trial to our knowledge which is specifically designed to address the potential beneficial effects of exercise in cancer patients with bone metastases.</offsets></p></sec><sec><title><offsets xml_i="14071" xml_f="14085" txt_i="7024" txt_f="7038">Methods/Design</offsets></title><p><offsets xml_i="14096" xml_f="14579" txt_i="7039" txt_f="7522">This is a two-armed prospective randomized controlled trial that will examine the efficacy and safety of a modular multi-modal physical exercise program in prostate cancer survivors with bone metastases. The trial will be a multisite study with clinical sites in Western Australia and New South Wales. Participants randomly assigned to the M3EP exercise intervention group will receive a 3-month supervised exercise intervention program (based on bone lesion location/extent) (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="14611" xml_f="14612" txt_i="7522" txt_f="7523">1</offsets></xref><offsets xml_i="14619" xml_f="14878" txt_i="7523" txt_f="7782">). Participants in the usual medical care group will be asked not to change their baseline levels of physical activity and will be offered the same exercise program after the 3-month control period if the intervention is deemed to be feasible and efficacious.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="14926" xml_f="14933" txt_i="7783" txt_f="7790">Table 1</offsets></label><caption><p><offsets xml_i="14953" xml_f="14976" txt_i="7790" txt_f="7813">Summary of study design</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center"><offsets xml_i="15057" xml_f="15063" txt_i="7814" txt_f="7820">Months</offsets></th><th align="center"><offsets xml_i="15087" xml_f="15088" txt_i="7820" txt_f="7821">0</offsets></th><th colspan="2"></th><th align="center"><offsets xml_i="15133" xml_f="15134" txt_i="7821" txt_f="7822">3</offsets></th><th colspan="2"></th><th align="center"><offsets xml_i="15179" xml_f="15180" txt_i="7822" txt_f="7823">6</offsets></th></tr></thead><tbody><tr><td align="center"><bold><offsets xml_i="15234" xml_f="15243" txt_i="7823" txt_f="7832">Exercise </offsets></bold><offsets xml_i="15250" xml_f="15256" txt_i="7832" txt_f="7838">(M3EP)</offsets></td><td></td><td align="center" colspan="2"><offsets xml_i="15301" xml_f="15322" txt_i="7840" txt_f="7861">Intervention (n = 45)</offsets></td><td></td><td align="center" colspan="2"><offsets xml_i="15367" xml_f="15391" txt_i="7863" txt_f="7887">Follow-up from 3-6 month</offsets></td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold><offsets xml_i="15478" xml_f="15496" txt_i="7890" txt_f="7908">Usual Medical Care</offsets></bold></td><td></td><td align="center" colspan="2"><offsets xml_i="15548" xml_f="15567" txt_i="7910" txt_f="7929">Usual Care (n = 45)</offsets></td><td></td><td align="center" colspan="2"><bold><offsets xml_i="15618" xml_f="15637" txt_i="7931" txt_f="7950">Usual Medical Care </offsets></bold><offsets xml_i="15644" xml_f="15694" txt_i="7950" txt_f="8000">to receive same intervention (M3EP) from 3-6 month</offsets></td><td></td></tr></tbody></table></table-wrap><sec><title><offsets xml_i="15754" xml_f="15765" txt_i="8002" txt_f="8013">Recruitment</offsets></title><p><offsets xml_i="15776" xml_f="15998" txt_i="8014" txt_f="8236">Subjects will be recruited by invitation of their specialist (radiation oncologist/urologists). Those entering the study will undertake a series of familiarisation sessions and baseline measurements prior to randomisation.</offsets></p></sec><sec><title><offsets xml_i="16020" xml_f="16033" txt_i="8238" txt_f="8251">Randomisation</offsets></title><p><offsets xml_i="16044" xml_f="16650" txt_i="8252" txt_f="8858">Patients will be randomly allocated in a ratio of 1:1 to the two study arms for the experimental M3EP exercise intervention or usual medical care groups, subject to maintaining approximate balance regarding stratification for current chemotherapy (yes/no). A research methods consultant with no patient contact will be responsible for randomisation. The exercise physiologists and other researchers conducting the study measures will be blinded to a given participant's group allocation. The exercise intervention will be provided by exercise physiologists not in the research team or performing the tests.</offsets></p></sec><sec><title><offsets xml_i="16672" xml_f="16680" txt_i="8860" txt_f="8868">Subjects</offsets></title><p><offsets xml_i="16691" xml_f="17460" txt_i="8869" txt_f="9638">Ninety men (45 subjects per arm) with prostate cancer and established bone metastases with no regular exercise (undertaking structured aerobic or resistance training two or more times per week) within the past 3 months will be recruited through invitation by their attending specialist in Perth, Western Australia, and the Central Coast region of New South Wales. All participants will require physician consent. Exclusion criteria will include acute illness, significant bone pain, musculoskeletal or cardiovascular or neurological disorders that could inhibit or put them at risk from exercising. The protocol has been approved (ID: 7699 GALVÃO) by the Edith Cowan University Human Research Ethics Committee and all participants will provide written informed consent.</offsets></p></sec><sec><title><offsets xml_i="17482" xml_f="17508" txt_i="9640" txt_f="9666">Calculation of sample size</offsets></title><p><offsets xml_i="17519" xml_f="18704" txt_i="9667" txt_f="10852">Data from our research team in prostate cancer patients indicates that the standard deviation (SD) for change in our primary outcome which is the physical function subscale of the Medical Outcomes Study Short-Form 36 (SF-36) equates to ~12 points following a 3-month intervention. Given the health status of men in the proposed study we anticipate that our 3-month exercise regimen will result in an increase of ~5 points in the physical function subscale of the SF-36 whereas the usual medical care group will result in an overall loss of ~3 points over 3 months. Therefore, we anticipate a difference between the exercise and usual medical care groups of ~8 points in change of the physical function subscale from baseline to 3 months. A priori, 36 subjects per group will be required to achieve 80% power at an alpha level of 0.05 (two-tailed), and to demonstrate a difference between groups at the end of the 3-month intervention. Therefore, to adequately ensure that we have sufficient subject numbers at the end of the intervention (accounting for a drop-out rate of ~20%), 90 subjects will be randomized in a ratio of 1:1 to exercise and usual medical care groups, respectively.</offsets></p></sec><sec><title><offsets xml_i="18726" xml_f="18738" txt_i="10854" txt_f="10866">Measurements</offsets></title><p><offsets xml_i="18749" xml_f="18885" txt_i="10867" txt_f="11003">Measurements for primary and secondary endpoints will take place at baseline, 3 months (end of the intervention) and 6 months follow-up.</offsets></p><sec><title><offsets xml_i="18901" xml_f="18924" txt_i="11004" txt_f="11027">Primary study endpoints</offsets></title><sec><title><offsets xml_i="18944" xml_f="18961" txt_i="11028" txt_f="11045">Physical function</offsets></title><p><offsets xml_i="18972" xml_f="19136" txt_i="11046" txt_f="11210">The physical function subscale of the Medical Outcomes Study Short-Form 36 (SF-36) questionnaire will be used as an indicator of patient rated physical functioning.</offsets></p></sec></sec><sec><title><offsets xml_i="19164" xml_f="19189" txt_i="11213" txt_f="11238">Secondary study endpoints</offsets></title><sec><title><offsets xml_i="19209" xml_f="19248" txt_i="11239" txt_f="11278">Objective measures of physical function</offsets></title><p><offsets xml_i="19259" xml_f="19325" txt_i="11279" txt_f="11345">A battery of tests will be used to assess functional performance [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="19357" xml_f="19359" txt_i="11345" txt_f="11347">22</offsets></xref><offsets xml_i="19366" xml_f="19367" txt_i="11347" txt_f="11348">,</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="19399" xml_f="19401" txt_i="11348" txt_f="11350">23</offsets></xref><offsets xml_i="19408" xml_f="19409" txt_i="11350" txt_f="11351">,</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="19441" xml_f="19443" txt_i="11351" txt_f="11353">27</offsets></xref><offsets xml_i="19450" xml_f="19969" txt_i="11353" txt_f="11872">]. Tests will be performed in triplicate (except for the 400-m walk which will be performed once) with sufficient recovery time between trials. The best performance on each test will be used in the analyses. The tests will be: 1) timed up and go, 2) 6-meter walk, usual and fast pace, and 3) 400-m walk. Participants with proximal femur bone lesion will be excluded from the 400-m walk test. Performance in each test will be timed electronically using a Kinematic Measurement System (Fitness Technology, SA, Australia).</offsets></p></sec><sec><title><offsets xml_i="19991" xml_f="20006" txt_i="11874" txt_f="11889">Muscle strength</offsets></title><p><offsets xml_i="20017" xml_f="20135" txt_i="11890" txt_f="12008">Dynamic muscular strength of the upper and lower body will be assessed using the one repetition maximum (1RM) method [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="20167" xml_f="20169" txt_i="12008" txt_f="12010">28</offsets></xref><offsets xml_i="20176" xml_f="20469" txt_i="12010" txt_f="12303">]. The 1RM is the maximal weight an individual can move through a full range of motion without change in body position other than that dictated by the specific exercise motion. Participants will perform 1RM tests for the knee extension and chest press exercises using a standard 1RM protocol [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="20501" xml_f="20503" txt_i="12303" txt_f="12305">23</offsets></xref><offsets xml_i="20510" xml_f="20816" txt_i="12305" txt_f="12611">]. Participants with proximal femur bone lesion will be excluded from leg extension 1-RM. Participants with axial skeleton (thoracic/ribs) bone lesion will be excluded from chest press 1-RM. These exercises were selected as they do not involve compression of the spine or excessive load in the pelvic area.</offsets></p></sec><sec><title><offsets xml_i="20838" xml_f="20865" txt_i="12613" txt_f="12640">Balance and risk of falling</offsets></title><p><offsets xml_i="20876" xml_f="21191" txt_i="12641" txt_f="12956">A Neurocom Smart Balancemaster (Neurocom, OR, USA) will be used to assess static and dynamic balance. This device measures ground reaction force to track whole body centre of pressure and a tilting visual field and support platform to separate the visual, somatosensory and vestibular balance sense of the patient [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="21223" xml_f="21225" txt_i="12956" txt_f="12958">23</offsets></xref><offsets xml_i="21232" xml_f="21330" txt_i="12958" txt_f="13056">]. Falls self-efficacy will be determined using the Activities-Specific Balance Confidence scale [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="21362" xml_f="21364" txt_i="13056" txt_f="13058">29</offsets></xref><offsets xml_i="21371" xml_f="21521" txt_i="13058" txt_f="13208">]. During the course of the intervention, all participants will record any falls that take place and submit monthly fall records to the investigators.</offsets></p></sec><sec><title><offsets xml_i="21543" xml_f="21573" txt_i="13210" txt_f="13240">Safety of the exercise program</offsets></title><p><offsets xml_i="21584" xml_f="21858" txt_i="13241" txt_f="13515">The safety of the exercise program will be assessed by recording the incidence and severity of any adverse events and skeletal complications throughout the intervention. Skeletal complications include pain at known bone metastases sites and pathological skeletal fractures [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="21890" xml_f="21892" txt_i="13515" txt_f="13517">17</offsets></xref><offsets xml_i="21899" xml_f="22434" txt_i="13517" txt_f="14052">]. Bone pain will be monitored according to the Common Terminology Criteria of the National Cancer Institute: grade 1 mild, not interfering with function; grade 2 moderate pain interfering with function but not interfering with the activities of daily life; and grade 3 severe pain, severely interfering with the activities of daily living. In the presence of bone pain, patients will cease the exercise program and undergo standard clinical evaluation, including plain x-rays and other more specialised imaging, as deemed appropriate.</offsets></p></sec><sec><title><offsets xml_i="22456" xml_f="22472" txt_i="14054" txt_f="14070">Body composition</offsets></title><p><offsets xml_i="22483" xml_f="22909" txt_i="14071" txt_f="14497">Regional and whole body lean mass (including appendicular skeletal muscle mass) and fat mass will be derived from a whole body dual-energy X-ray absorptiometry scan (Hologic Discovery A, Waltham, MA). Measurement of trunk adiposity is an important indicator of chronic disease risk, and will be assessed from trunk fat mass obtained from the whole body scan and the ratios of trunk fat to limb fat, and trunk fat to total fat.</offsets></p></sec><sec><title><offsets xml_i="22931" xml_f="22970" txt_i="14499" txt_f="14538">Muscle density and cross-sectional area</offsets></title><p><offsets xml_i="22981" xml_f="23244" txt_i="14539" txt_f="14802">Peripheral Quantitative Computed Tomography (XCT3000, Stratec, Pforzheim, Germany) will be used to measure muscle density (an indicator of fat infiltration within the muscle and hence muscle quality) and muscle cross-sectional areas of the upper and lower limbs [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="23276" xml_f="23278" txt_i="14802" txt_f="14804">30</offsets></xref><offsets xml_i="23285" xml_f="23287" txt_i="14804" txt_f="14806">].</offsets></p></sec><sec><title><offsets xml_i="23309" xml_f="23385" txt_i="14808" txt_f="14884">Health-related quality of life, bone pain and the late life - function index</offsets></title><p><offsets xml_i="23396" xml_f="23559" txt_i="14885" txt_f="15048">Health-related quality of life outcomes on general health, pain, vitality, social functioning, emotional role, and mental health will be measured using the SF-36 [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="23591" xml_f="23593" txt_i="15048" txt_f="15050">31</offsets></xref><offsets xml_i="23600" xml_f="23706" txt_i="15050" txt_f="15156">]. The FACIT-Bone Pain questionnaire will be used to assess the nature, severity and impact of bone pain [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="23738" xml_f="23740" txt_i="15156" txt_f="15158">32</offsets></xref><offsets xml_i="23747" xml_f="23851" txt_i="15158" txt_f="15262">]. The Late Life - Function Index (LL-FI) will be used to assess patient-reported physical functioning [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="23883" xml_f="23885" txt_i="15262" txt_f="15264">33</offsets></xref><offsets xml_i="23892" xml_f="23894" txt_i="15264" txt_f="15266">].</offsets></p></sec><sec><title><offsets xml_i="23916" xml_f="23938" txt_i="15268" txt_f="15290">Anxiety and depression</offsets></title><p><offsets xml_i="23949" xml_f="24108" txt_i="15291" txt_f="15450">The Brief Symptom Inventory-18 will provide a global measure of current psychological distress with subscale scores for anxiety, depression, and somatisation [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="24140" xml_f="24142" txt_i="15450" txt_f="15452">34</offsets></xref><offsets xml_i="24149" xml_f="24151" txt_i="15452" txt_f="15454">].</offsets></p></sec><sec><title><offsets xml_i="24173" xml_f="24197" txt_i="15456" txt_f="15480">Cancer specific distress</offsets></title><p><offsets xml_i="24208" xml_f="24351" txt_i="15481" txt_f="15624">The Impact of Events Scale (IES) and the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) will be used to measure cancer specific distress [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="24383" xml_f="24385" txt_i="15624" txt_f="15626">35</offsets></xref><offsets xml_i="24392" xml_f="24393" txt_i="15626" txt_f="15627">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="24425" xml_f="24427" txt_i="15627" txt_f="15629">36</offsets></xref><offsets xml_i="24434" xml_f="24511" txt_i="15629" txt_f="15706">]. The IES has 15 items and contains two subscales: Intrusion and Avoidance [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="24543" xml_f="24545" txt_i="15706" txt_f="15708">36</offsets></xref><offsets xml_i="24552" xml_f="24812" txt_i="15708" txt_f="15968">]. Intrusion can also be used as a proxy measure for rumination about cancer. The MAX-PC consists of 18 items and assesses cancer specific distress across three domains: Prostate Cancer Anxiety; Prostate Specific Antigen (PSA) Anxiety; and Fear of Recurrence [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="24844" xml_f="24846" txt_i="15968" txt_f="15970">35</offsets></xref><offsets xml_i="24853" xml_f="24855" txt_i="15970" txt_f="15972">].</offsets></p></sec><sec><title><offsets xml_i="24877" xml_f="24884" txt_i="15974" txt_f="15981">Fatigue</offsets></title><p><offsets xml_i="24895" xml_f="25095" txt_i="15982" txt_f="16182">Fatigue will be assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. The FACIT-F is a 13-item scale commonly used to assess fatigue in cancer patients [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="25127" xml_f="25129" txt_i="16182" txt_f="16184">37</offsets></xref><offsets xml_i="25136" xml_f="25199" txt_i="16184" txt_f="16247">] as well as cancer patients receiving exercise interventions [</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="25231" xml_f="25233" txt_i="16247" txt_f="16249">38</offsets></xref><offsets xml_i="25240" xml_f="25242" txt_i="16249" txt_f="16251">].</offsets></p></sec><sec><title><offsets xml_i="25264" xml_f="25277" txt_i="16253" txt_f="16266">Sleep quality</offsets></title><p><offsets xml_i="25288" xml_f="25380" txt_i="16267" txt_f="16359">Items from the Pittsburgh Sleep Quality Index (PSQI) will be used to measure sleep quality [</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="25412" xml_f="25414" txt_i="16359" txt_f="16361">39</offsets></xref><offsets xml_i="25421" xml_f="25551" txt_i="16361" txt_f="16491">]. The PSQI is used to asses quality of sleep over a 1-month interval, and has been shown to be reliable and sensitive to change [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="25583" xml_f="25585" txt_i="16491" txt_f="16493">40</offsets></xref><offsets xml_i="25592" xml_f="25594" txt_i="16493" txt_f="16495">].</offsets></p></sec><sec><title><offsets xml_i="25616" xml_f="25644" txt_i="16497" txt_f="16525">Physical activity motivation</offsets></title><p><offsets xml_i="25655" xml_f="25808" txt_i="16526" txt_f="16679">The Theory of Planned Behaviour (TPB) is the most widely utilised behavioural framework when examining physical activity motivation in cancer survivors [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="25840" xml_f="25842" txt_i="16679" txt_f="16681">41</offsets></xref><offsets xml_i="25849" xml_f="26154" txt_i="16681" txt_f="16986">]. Therefore, physical activity motivation will be assessed in accordance with the TPB. TPB constructs (affective and instrumental attitude, injunctive and descriptive norm, self-efficacy, perceived behavioural control, intention, and planning) will be assessed in accordance with established guidelines [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="26186" xml_f="26188" txt_i="16986" txt_f="16988">41</offsets></xref><offsets xml_i="26195" xml_f="26197" txt_i="16988" txt_f="16990">].</offsets></p></sec><sec><title><offsets xml_i="26219" xml_f="26242" txt_i="16992" txt_f="17015">Physical activity level</offsets></title><p><offsets xml_i="26253" xml_f="26481" txt_i="17016" txt_f="17244">Self report physical activity level will be assessed by the Godin Leisure-Time Questionnaire. ActiGraph activity monitors (triaxial accelerometer) will be used to objectively assess physical activity levels over a 7-day period [</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="26513" xml_f="26515" txt_i="17244" txt_f="17246">42</offsets></xref><offsets xml_i="26522" xml_f="26614" txt_i="17246" txt_f="17338">]. A 6-item sedentary questionnaire will be used to assess the level of sedentary behaviour.</offsets></p></sec><sec><title><offsets xml_i="26636" xml_f="26660" txt_i="17340" txt_f="17364">Tolerance of the program</offsets></title><p><offsets xml_i="26671" xml_f="27109" txt_i="17365" txt_f="17803">Tolerance of the exercise program will be evaluated by recording participants' ratings of perceived exertion on a Borg scale after every exercise session. Additionally, a custom designed survey examining exercise tolerance using a 7-point Likert scale will be administered prior to the first exercise session each week. The number of participants completing the 3-month program as well as the number of sessions attended will be recorded.</offsets></p></sec></sec><sec><title><offsets xml_i="27137" xml_f="27162" txt_i="17806" txt_f="17831">Other monitoring measures</offsets></title><sec><title><offsets xml_i="27182" xml_f="27213" txt_i="17832" txt_f="17863">Prostate specific antigen (PSA)</offsets></title><p><offsets xml_i="27224" xml_f="27437" txt_i="17864" txt_f="18077">PSA will be assessed at baseline, 3 months (end of the intervention) and 6 months follow-up by an accredited National Association of Testing Authorities laboratory (Pathwest Diagnostics, Perth, Western Australia).</offsets></p></sec></sec><sec><title><offsets xml_i="27465" xml_f="27486" txt_i="18080" txt_f="18101">Exercise intervention</offsets></title><p><offsets xml_i="27497" xml_f="28142" txt_i="18102" txt_f="18747">The modular multi-modal physical exercise intervention program (M3EP) will comprise resistance, aerobic and flexibility exercises undertaken 3 times per week in an exercise clinic setting supervised by an exercise physiologist. Exercise training sessions will take approximately 60 min (this includes the warm-up and cool-down periods) and will be conducted in the Exercise Clinics at Edith Cowan University in Perth, and at the University of Newcastle's Central Coast campus in Ourimbah. The programme will include 6 exercises that target the major trunk, upper and lower body muscle groups, which we have used in a number of previous studies [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="28174" xml_f="28176" txt_i="18747" txt_f="18749">21</offsets></xref><offsets xml_i="28183" xml_f="28184" txt_i="18749" txt_f="18750">-</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="28216" xml_f="28218" txt_i="18750" txt_f="18752">23</offsets></xref><offsets xml_i="28225" xml_f="28226" txt_i="18752" txt_f="18753">,</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="28258" xml_f="28260" txt_i="18753" txt_f="18755">27</offsets></xref><offsets xml_i="28267" xml_f="28268" txt_i="18755" txt_f="18756">,</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="28300" xml_f="28302" txt_i="18756" txt_f="18758">43</offsets></xref><offsets xml_i="28309" xml_f="28310" txt_i="18758" txt_f="18759">-</offsets><xref ref-type="bibr" rid="B46"><offsets xml_i="28342" xml_f="28344" txt_i="18759" txt_f="18761">46</offsets></xref><offsets xml_i="28351" xml_f="28501" txt_i="18761" txt_f="18911">] including men on ADT. There will be a modular component for the resistance exercise prescription based on location/extent of bone metastases (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="28533" xml_f="28534" txt_i="18911" txt_f="18912">2</offsets></xref><offsets xml_i="28541" xml_f="29956" txt_i="18912" txt_f="20327">). To ensure the progressive nature of the training program, subjects will be encouraged to work past the specific repetition maximums (RMs) prescribed. The resistance will be increased by 5-10% increment for the next set/training session if subjects are able to perform more repetitions than the RMs specified during a set. Moderate intensity and volume of resistance exercise will range from 10 to 12-RM (e.g. the maximal weight that can be lifted 10 to 12 times) using 3 sets per exercise. This program differs considerably from those commonly prescribed for survivors with localised prostate cancer. Specifically, the M3EP is designed to minimise compressive and shear loads on affected skeletal sites to account for the reduced load bearing capabilities of bone due to metastatic disease in specific regions. Such loading is considerably below the forces exerted on the skeleton during tasks of daily living such as descending stairs or stepping down from a height and will be similar to that of walking. All exercises will be performed at a set cadence of 2 s for both eccentric and concentric phases further minimizing peak forces transmitted to the skeleton. Aerobic exercise component of the M3EP will also be based on location/extent of bone metastases with those with pelvis, axial skeleton (lumbar), proximal femur and all regions bone metastatic disease undergoing non-weight bearing activities (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="29988" xml_f="29989" txt_i="20327" txt_f="20328">2</offsets></xref><offsets xml_i="29996" xml_f="30238" txt_i="20328" txt_f="20570">). The aerobic component will include 20-30 min of cardiovascular exercise using various modes such as walking on a treadmill, cycling or rowing a stationary ergometer, or exercising on a cross training machine based on disease extent (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="30270" xml_f="30271" txt_i="20570" txt_f="20571">2</offsets></xref><offsets xml_i="30278" xml_f="30720" txt_i="20571" txt_f="21013">). Target intensity will be 60%-85% estimated maximum heart rate (220 - age) with individual heart rate monitors (Polar Electro Oy, Finland) provided for each participant. The flexibility component of the M3EP will involve static stretching of all the joint ranges of motion considered important for function. Those with axial skeleton and all regions bone metastases will be excluded from undertaking spine flexion/extension/rotation (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="30752" xml_f="30753" txt_i="21013" txt_f="21014">2</offsets></xref><offsets xml_i="30760" xml_f="30858" txt_i="21014" txt_f="21112">). The protocol will involve 2-4 sets per muscle group at 30-60 s per set as previously proposed [</offsets><xref ref-type="bibr" rid="B47"><offsets xml_i="30890" xml_f="30892" txt_i="21112" txt_f="21114">47</offsets></xref><offsets xml_i="30899" xml_f="31871" txt_i="21114" txt_f="22086">]. All M3EP sessions will be conducted in small groups of up to 8 participants under direct supervision to ensure correct technique and minimal risk of injury. Each session will commence with a 10-minute warm-up comprising low-level aerobic activities such as treadmill walking and stationary cycling as determined by bone metastases site, as well as stretching and conclude with a 5-minute cool-down period of stretching activities. The M3EP will be designed to provide adequate stimulus to the cardiorespiratory, skeletal and neuromuscular systems while maximizing compliance and retention. All participants will be asked to maintain customary physical activity and dietary patterns over the intervention period (apart from the programmed exercise). Dietary intake will be assessed at baseline, 3 and 6 months using 3-day record. During the course of the study, participants will be required to maintain an activity log and record their recreational physical activities.</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="31919" xml_f="31926" txt_i="22087" txt_f="22094">Table 2</offsets></label><caption><p><offsets xml_i="31946" xml_f="32039" txt_i="22094" txt_f="22187">Modular multi-modal physical exercise program (M3EP) for prostate cancer with bone metastases</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center"><offsets xml_i="32120" xml_f="32135" txt_i="22188" txt_f="22203">Metastases site</offsets></th><th align="center" colspan="6"><offsets xml_i="32171" xml_f="32184" txt_i="22203" txt_f="22216">Exercise mode</offsets></th></tr><tr><th></th><th colspan="6"><hr></hr></th></tr><tr><th></th><th align="center" colspan="3"><italic><offsets xml_i="32294" xml_f="32304" txt_i="22216" txt_f="22226">Resistance</offsets></italic></th><th align="center" colspan="2"><italic><offsets xml_i="32357" xml_f="32364" txt_i="22226" txt_f="22233">Aerobic</offsets></italic></th><th align="center"><italic><offsets xml_i="32405" xml_f="32416" txt_i="22233" txt_f="22244">Flexibility</offsets></italic></th></tr></thead><tbody><tr><td></td><td align="center"><bold><offsets xml_i="32488" xml_f="32493" txt_i="22245" txt_f="22250">Upper</offsets></bold></td><td align="center"><bold><offsets xml_i="32530" xml_f="32535" txt_i="22251" txt_f="22256">Trunk</offsets></bold></td><td align="center"><bold><offsets xml_i="32572" xml_f="32577" txt_i="22257" txt_f="22262">Lower</offsets></bold></td><td align="center"><bold><offsets xml_i="32614" xml_f="32616" txt_i="22263" txt_f="22265">WB</offsets></bold></td><td align="center"><bold><offsets xml_i="32653" xml_f="32656" txt_i="22266" txt_f="22269">NWB</offsets></bold></td><td align="center"><bold><offsets xml_i="32693" xml_f="32700" txt_i="22270" txt_f="22277">Static </offsets></bold></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="32777" xml_f="32783" txt_i="22279" txt_f="22285">Pelvis</offsets></td><td align="center"><offsets xml_i="32807" xml_f="32808" txt_i="22286" txt_f="22287">√</offsets></td><td align="center"><offsets xml_i="32832" xml_f="32833" txt_i="22288" txt_f="22289">√</offsets></td><td align="center"><offsets xml_i="32857" xml_f="32860" txt_i="22290" txt_f="22293">√**</offsets></td><td align="center"></td><td align="center"><offsets xml_i="32908" xml_f="32909" txt_i="22295" txt_f="22296">√</offsets></td><td align="center"><offsets xml_i="32933" xml_f="32934" txt_i="22297" txt_f="22298">√</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="33004" xml_f="33027" txt_i="22300" txt_f="22323">Axial Skeleton (lumbar)</offsets></td><td align="center"><offsets xml_i="33051" xml_f="33052" txt_i="22324" txt_f="22325">√</offsets></td><td align="center"></td><td align="center"><offsets xml_i="33100" xml_f="33101" txt_i="22327" txt_f="22328">√</offsets></td><td align="center"></td><td align="center"><offsets xml_i="33149" xml_f="33150" txt_i="22330" txt_f="22331">√</offsets></td><td align="center"><offsets xml_i="33174" xml_f="33178" txt_i="22332" txt_f="22336">√***</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="33248" xml_f="33278" txt_i="22338" txt_f="22368">Axial Skeleton (thoracic/ribs)</offsets></td><td align="center"><offsets xml_i="33302" xml_f="33304" txt_i="22369" txt_f="22371">√*</offsets></td><td align="center"></td><td align="center"><offsets xml_i="33352" xml_f="33353" txt_i="22373" txt_f="22374">√</offsets></td><td align="center"><offsets xml_i="33377" xml_f="33378" txt_i="22375" txt_f="22376">√</offsets></td><td align="center"><offsets xml_i="33402" xml_f="33403" txt_i="22377" txt_f="22378">√</offsets></td><td align="center"><offsets xml_i="33427" xml_f="33431" txt_i="22379" txt_f="22383">√***</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="33501" xml_f="33515" txt_i="22385" txt_f="22399">Proximal Femur</offsets></td><td align="center"><offsets xml_i="33539" xml_f="33540" txt_i="22400" txt_f="22401">√</offsets></td><td align="center"><offsets xml_i="33564" xml_f="33565" txt_i="22402" txt_f="22403">√</offsets></td><td align="center"><offsets xml_i="33589" xml_f="33592" txt_i="22404" txt_f="22407">√**</offsets></td><td align="center"></td><td align="center"><offsets xml_i="33640" xml_f="33641" txt_i="22409" txt_f="22410">√</offsets></td><td align="center"><offsets xml_i="33665" xml_f="33666" txt_i="22411" txt_f="22412">√</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="33736" xml_f="33747" txt_i="22414" txt_f="22425">All regions</offsets></td><td align="center"><offsets xml_i="33771" xml_f="33773" txt_i="22426" txt_f="22428">√*</offsets></td><td align="center"></td><td align="center"><offsets xml_i="33821" xml_f="33824" txt_i="22430" txt_f="22433">√**</offsets></td><td align="center"></td><td align="center"><offsets xml_i="33872" xml_f="33873" txt_i="22435" txt_f="22436">√</offsets></td><td align="center"><offsets xml_i="33897" xml_f="33901" txt_i="22437" txt_f="22441">√***</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="33947" xml_f="34158" txt_i="22442" txt_f="22653">√ = Target exercise region; * = exclusion of shoulder flexion/extension/abduction/adduction - inclusion of elbow flexion/extension; ** = exclusion of hip extension/flexion - inclusion of knee extension/flexion; </offsets><italic><offsets xml_i="34166" xml_f="34169" txt_i="22653" txt_f="22656">WB </offsets></italic><offsets xml_i="34178" xml_f="34209" txt_i="22656" txt_f="22687">weight bearing (e.g. walking); </offsets><italic><offsets xml_i="34217" xml_f="34221" txt_i="22687" txt_f="22691">NWB </offsets></italic><offsets xml_i="34230" xml_f="34317" txt_i="22691" txt_f="22778">non-weight bearing (e.g. cycling); *** = exclusion of spine/flexion/extension/rotation.</offsets></p></table-wrap-foot></table-wrap></sec></sec><sec><title><offsets xml_i="34376" xml_f="34396" txt_i="22781" txt_f="22801">Statistical analysis</offsets></title><p><offsets xml_i="34407" xml_f="34872" txt_i="22802" txt_f="23267">Data will be analysed using the SPSS statistical software package and an intention-to-treat approach will be applied. Analyses will include standard descriptive statistics, Student's t tests, correlation and regression, and two-way (group × time) repeated measures ANOVA (or ANCOVA as appropriate) to examine differences between groups over time. All tests will be two-tailed and an alpha level of 0.05 will be applied as the criterion for statistical significance.</offsets></p></sec></sec><sec><title><offsets xml_i="34900" xml_f="34910" txt_i="23270" txt_f="23280">Discussion</offsets></title><p><offsets xml_i="34921" xml_f="35084" txt_i="23281" txt_f="23444">Prostate cancer patients with bone metastases experience considerable morbidity resulting from skeletal complications and often fatigue secondary to chemotherapy [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="35115" xml_f="35116" txt_i="23444" txt_f="23445">3</offsets></xref><offsets xml_i="35123" xml_f="35124" txt_i="23445" txt_f="23446">,</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="35155" xml_f="35156" txt_i="23446" txt_f="23447">7</offsets></xref><offsets xml_i="35163" xml_f="37063" txt_i="23447" txt_f="25347">]. Delaying or preventing skeletal complication and improving physical function for men with bone metastases would provide clinically meaningful benefits to patients. However, exercise programs must be designed and executed with careful consideration of the skeletal complications associated with bone metastatic disease and cumulative toxicities from androgen deprivation such as osteoporosis and increased risk of fractures. Currently, such patients are unable to follow existing exercise guidelines established for patients with localised prostate cancer given the absence of exercise-related data for this population. Consequently, the results from this study will form the basis for the development of a specific exercise prescription in this patient group in order to alleviate disease burden, counteract the adverse treatment related side-effects and enhance quality of life. This project is unique as it will be the first study examining if a modular multi-modal targeted exercise program incorporating resistance, aerobic and flexibility exercise is safe and well tolerated by prostate cancer patients with bone metastases. In terms of advancement of prostate cancer care, we expect dissemination of the knowledge gained from this project to reduce fracture risk, improve physical and functional ability, quality of life and ultimately survival rates in this population. Lastly, the proposed study will provide strong, innovative information that has the potential to directly influence current clinical recommendations for other advanced cancer patients with bone metastases. Although the intervention in this study will be highly supervised and targeted to patient's specific needs, given the nature of the modular prescription approach, it has the potential to be performed and implemented in different centres and at the community level thereby reaching a significant number of patients.</offsets></p></sec><sec><title><offsets xml_i="37085" xml_f="37098" txt_i="25349" txt_f="25362">Abbreviations</offsets></title><p><offsets xml_i="37109" xml_f="37523" txt_i="25363" txt_f="25777">ADT: Androgen deprivation therapy; IES: Impact of events scale; MAX-PC: Memorial anxiety scale for prostate cancer; M3EP: Modular multi-modal exercise program; PSA: Prostate specific antigen; SF-36: Medical outcomes study short-form 36; FACIT-F: Functional assessment of chronic illness therapy-fatigue; TPB: Theory of planned behaviour; LL-FI: The late life - function index; PSQI: Pittsburgh sleep quality index.</offsets></p></sec><sec><title><offsets xml_i="37545" xml_f="37564" txt_i="25779" txt_f="25798">Competing interests</offsets></title><p><offsets xml_i="37575" xml_f="37633" txt_i="25799" txt_f="25857">The authors declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="37655" xml_f="37677" txt_i="25859" txt_f="25881">Authors' contributions</offsets></title><p><offsets xml_i="37688" xml_f="38105" txt_i="25882" txt_f="26299">DAG, PC, NS, DRT, and RUN developed the study concept and protocols and initiated the project. SKC, CPM, MB, JD, GG and DJ assisted in further development of the protocol. DAG, PC, DRT and RUN drafted the manuscript. NS, JD, and DJ will provide access to patients. DAG, PC, DRT, CPM, MB and RUN will implement the protocol and oversee collection of the data. All authors contributed and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="38127" xml_f="38150" txt_i="26301" txt_f="26324">Pre-publication history</offsets></title><p><offsets xml_i="38161" xml_f="38225" txt_i="26325" txt_f="26389">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/11/517/prepub"><offsets xml_i="38328" xml_f="38380" txt_i="26390" txt_f="26442">http://www.biomedcentral.com/1471-2407/11/517/prepub</offsets></ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>This study was funded by Movember through Prostate Cancer Foundation of Australia's Research Program ID: NDDA151. DAG is funded by a Movember New Directions Development Award obtained through Prostate Cancer Foundation of Australia's Research Program. SKC is supported by an Australian National Health and Medical Research Council Fellowship (ID 496003). PC is supported by the Cancer Council Western Australia Postdoctoral Research Fellowship.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Smith</surname><given-names>MR</given-names></name><name><surname>Seaman</surname><given-names>JJ</given-names></name><name><surname>Petrone</surname><given-names>S</given-names></name><name><surname>Kowalski</surname><given-names>MO</given-names></name><article-title>Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><issue>23</issue><fpage>4277</fpage><lpage>4284</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.05.147</pub-id><pub-id pub-id-type="pmid">14581438</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Fizazi</surname><given-names>K</given-names></name><name><surname>Beuzeboc</surname><given-names>P</given-names></name><name><surname>Lumbroso</surname><given-names>J</given-names></name><name><surname>Haddad</surname><given-names>V</given-names></name><name><surname>Massard</surname><given-names>C</given-names></name><name><surname>Gross-Goupil</surname><given-names>M</given-names></name><name><surname>Di Palma</surname><given-names>M</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Theodore</surname><given-names>C</given-names></name><name><surname>Loriot</surname><given-names>Y</given-names></name><etal></etal><article-title>Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>15</issue><fpage>2429</fpage><lpage>2435</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.9811</pub-id><pub-id pub-id-type="pmid">19364971</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Carlin</surname><given-names>BI</given-names></name><name><surname>Andriole</surname><given-names>GL</given-names></name><article-title>The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma</article-title><source>Cancer</source><year>2000</year><volume>88</volume><issue>12 Suppl</issue><fpage>2989</fpage><lpage>2994</lpage><pub-id pub-id-type="pmid">10898342</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Saad</surname><given-names>F</given-names></name><name><surname>Olsson</surname><given-names>C</given-names></name><name><surname>Schulman</surname><given-names>CC</given-names></name><article-title>Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care</article-title><source>Eur Urol</source><year>2004</year><volume>46</volume><issue>6</issue><fpage>731</fpage><lpage>739</lpage><comment>discussion 739-740</comment><pub-id pub-id-type="doi">10.1016/j.eururo.2004.08.016</pub-id><pub-id pub-id-type="pmid">15548440</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><article-title>Cancer statistics</article-title><source>CA Cancer J Clin</source><year>2010</year><volume>60</volume><issue>5</issue><fpage>277</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.3322/caac.20073</pub-id><pub-id pub-id-type="pmid">20610543</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Saylor</surname><given-names>PJ</given-names></name><name><surname>Smith</surname><given-names>MR</given-names></name><article-title>Treatment and prevention of bone complications from prostate cancer</article-title><source>Bone</source><year>2011</year><volume>48</volume><issue>1</issue><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2010.05.038</pub-id><pub-id pub-id-type="pmid">20621630</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Weinfurt</surname><given-names>KP</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Castel</surname><given-names>LD</given-names></name><name><surname>Saad</surname><given-names>F</given-names></name><name><surname>Timbie</surname><given-names>JW</given-names></name><name><surname>Glendenning</surname><given-names>GA</given-names></name><name><surname>Schulman</surname><given-names>KA</given-names></name><article-title>The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><issue>4</issue><fpage>579</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi122</pub-id><pub-id pub-id-type="pmid">15734776</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Shahinian</surname><given-names>VB</given-names></name><name><surname>Kuo</surname><given-names>YF</given-names></name><name><surname>Freeman</surname><given-names>JL</given-names></name><name><surname>Goodwin</surname><given-names>JS</given-names></name><article-title>Risk of fracture after androgen deprivation for prostate cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>2</issue><fpage>154</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa041943</pub-id><pub-id pub-id-type="pmid">15647578</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Sharifi</surname><given-names>N</given-names></name><name><surname>Gulley</surname><given-names>JL</given-names></name><name><surname>Dahut</surname><given-names>WL</given-names></name><article-title>Androgen deprivation therapy for prostate cancer</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>2</issue><fpage>238</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1001/jama.294.2.238</pub-id><pub-id pub-id-type="pmid">16014598</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Diamond</surname><given-names>TH</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Smith</surname><given-names>MR</given-names></name><name><surname>Guise</surname><given-names>TA</given-names></name><name><surname>Singer</surname><given-names>FR</given-names></name><article-title>Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies</article-title><source>Cancer</source><year>2004</year><volume>100</volume><issue>5</issue><fpage>892</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1002/cncr.20056</pub-id><pub-id pub-id-type="pmid">14983482</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Spry</surname><given-names>NA</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><name><surname>Stanley</surname><given-names>J</given-names></name><name><surname>Shannon</surname><given-names>T</given-names></name><name><surname>Rowling</surname><given-names>C</given-names></name><name><surname>Prince</surname><given-names>R</given-names></name><article-title>Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer</article-title><source>BJU Int</source><year>2008</year><volume>102</volume><issue>1</issue><fpage>44</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.07539.x</pub-id><pub-id pub-id-type="pmid">18336606</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Spry</surname><given-names>N</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><article-title>Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation</article-title><source>Prostate Cancer Prostatic Dis</source><year>2009</year><volume>12</volume><issue>2</issue><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1038/pcan.2008.51</pub-id><pub-id pub-id-type="pmid">18852703</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Ebeling</surname><given-names>PR</given-names></name><article-title>Clinical practice. Osteoporosis in men</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>14</issue><fpage>1474</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1056/NEJMcp0707217</pub-id><pub-id pub-id-type="pmid">18385499</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Oefelein</surname><given-names>MG</given-names></name><name><surname>Ricchiuti</surname><given-names>V</given-names></name><name><surname>Conrad</surname><given-names>W</given-names></name><name><surname>Resnick</surname><given-names>MI</given-names></name><article-title>Skeletal fractures negatively correlate with overall survival in men with prostate cancer</article-title><source>J Urol</source><year>2002</year><volume>168</volume><issue>3</issue><fpage>1005</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)64561-2</pub-id><pub-id pub-id-type="pmid">12187209</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Petrylak</surname><given-names>DP</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Hussain</surname><given-names>MH</given-names></name><name><surname>Lara</surname><given-names>PN</given-names><suffix>Jr</suffix></name><name><surname>Jones</surname><given-names>JA</given-names></name><name><surname>Taplin</surname><given-names>ME</given-names></name><name><surname>Burch</surname><given-names>PA</given-names></name><name><surname>Berry</surname><given-names>D</given-names></name><name><surname>Moinpour</surname><given-names>C</given-names></name><name><surname>Kohli</surname><given-names>M</given-names></name><etal></etal><article-title>Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><issue>15</issue><fpage>1513</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa041318</pub-id><pub-id pub-id-type="pmid">15470214</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Banu</surname><given-names>E</given-names></name><name><surname>Beuzeboc</surname><given-names>P</given-names></name><name><surname>Voog</surname><given-names>E</given-names></name><name><surname>Dourthe</surname><given-names>LM</given-names></name><name><surname>Hardy-Bessard</surname><given-names>AC</given-names></name><name><surname>Linassier</surname><given-names>C</given-names></name><name><surname>Scotte</surname><given-names>F</given-names></name><name><surname>Banu</surname><given-names>A</given-names></name><name><surname>Coscas</surname><given-names>Y</given-names></name><etal></etal><article-title>Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>15</issue><fpage>3343</fpage><lpage>3351</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.12.187</pub-id><pub-id pub-id-type="pmid">15738542</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Coleman</surname><given-names>RE</given-names></name><article-title>Metastatic bone disease: clinical features, pathophysiology and treatment strategies</article-title><source>Cancer Treat Rev</source><year>2001</year><volume>27</volume><issue>3</issue><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1053/ctrv.2000.0210</pub-id><pub-id pub-id-type="pmid">11417967</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Eton</surname><given-names>DT</given-names></name><name><surname>Lepore</surname><given-names>SJ</given-names></name><article-title>Prostate cancer and health-related quality of life: a review of the literature</article-title><source>Psychooncology</source><year>2002</year><volume>11</volume><issue>4</issue><fpage>307</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1002/pon.572</pub-id><pub-id pub-id-type="pmid">12203744</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Albertsen</surname><given-names>PC</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Muller</surname><given-names>MJ</given-names></name><name><surname>Keller</surname><given-names>SD</given-names></name><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><article-title>Health-related quality of life among patients with metastatic prostate cancer</article-title><source>Urology</source><year>1997</year><volume>49</volume><issue>2</issue><fpage>207</fpage><lpage>216</lpage><comment>discussion 216-207</comment><pub-id pub-id-type="doi">10.1016/S0090-4295(96)00485-2</pub-id><pub-id pub-id-type="pmid">9037282</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Windsor</surname><given-names>PM</given-names></name><name><surname>Nicol</surname><given-names>KF</given-names></name><name><surname>Potter</surname><given-names>J</given-names></name><article-title>A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma</article-title><source>Cancer</source><year>2004</year><volume>101</volume><issue>3</issue><fpage>550</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1002/cncr.20378</pub-id><pub-id pub-id-type="pmid">15274068</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Nosaka</surname><given-names>K</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Peake</surname><given-names>J</given-names></name><name><surname>Spry</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Yamaya</surname><given-names>K</given-names></name><name><surname>McGuigan</surname><given-names>MR</given-names></name><name><surname>Kristjanson</surname><given-names>LJ</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><article-title>Endocrine and immune responses to resistance training in prostate cancer patients</article-title><source>Prostate Cancer Prostatic Dis</source><year>2008</year><volume>11</volume><issue>2</issue><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/sj.pcan.4500991</pub-id><pub-id pub-id-type="pmid">17637762</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Spry</surname><given-names>N</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><article-title>Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>2</issue><fpage>340</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.2488</pub-id><pub-id pub-id-type="pmid">19949016</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Nosaka</surname><given-names>K</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Spry</surname><given-names>N</given-names></name><name><surname>Kristjanson</surname><given-names>LJ</given-names></name><name><surname>McGuigan</surname><given-names>MR</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Yamaya</surname><given-names>K</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><article-title>Resistance training and reduction of treatment side effects in prostate cancer patients</article-title><source>Med Sci Sports Exerc</source><year>2006</year><volume>38</volume><issue>12</issue><fpage>2045</fpage><lpage>2052</lpage><pub-id pub-id-type="doi">10.1249/01.mss.0000233803.48691.8b</pub-id><pub-id pub-id-type="pmid">17146309</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Segal</surname><given-names>RJ</given-names></name><name><surname>Reid</surname><given-names>RD</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Sigal</surname><given-names>RJ</given-names></name><name><surname>Kenny</surname><given-names>GP</given-names></name><name><surname>Prud'Homme</surname><given-names>DG</given-names></name><name><surname>Malone</surname><given-names>SC</given-names></name><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Scott</surname><given-names>CG</given-names></name><name><surname>Slovinec D'Angelo</surname><given-names>ME</given-names></name><article-title>Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>3</issue><fpage>344</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">19064985</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Segal</surname><given-names>RJ</given-names></name><name><surname>Reid</surname><given-names>RD</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Malone</surname><given-names>SC</given-names></name><name><surname>Parliament</surname><given-names>MB</given-names></name><name><surname>Scott</surname><given-names>CG</given-names></name><name><surname>Venner</surname><given-names>PM</given-names></name><name><surname>Quinney</surname><given-names>HA</given-names></name><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>D'Angelo</surname><given-names>ME</given-names></name><etal></etal><article-title>Resistance exercise in men receiving androgen deprivation therapy for prostate cancer</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><issue>9</issue><fpage>1653</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.09.534</pub-id><pub-id pub-id-type="pmid">12721238</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Schmitz</surname><given-names>KH</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Matthews</surname><given-names>C</given-names></name><name><surname>Demark-Wahnefried</surname><given-names>W</given-names></name><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Pinto</surname><given-names>BM</given-names></name><name><surname>Irwin</surname><given-names>ML</given-names></name><name><surname>Wolin</surname><given-names>KY</given-names></name><name><surname>Segal</surname><given-names>RJ</given-names></name><name><surname>Lucia</surname><given-names>A</given-names></name><etal></etal><article-title>American College of Sports Medicine roundtable on exercise guidelines for cancer survivors</article-title><source>Med Sci Sports Exerc</source><year>2010</year><volume>42</volume><issue>7</issue><fpage>1409</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1249/MSS.0b013e3181e0c112</pub-id><pub-id pub-id-type="pmid">20559064</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><article-title>Resistance exercise dosage in older adults: single- versus multiset effects on physical performance and body composition</article-title><source>J Am Geriatr Soc</source><year>2005</year><volume>53</volume><issue>12</issue><fpage>2090</fpage><lpage>2097</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.00494.x</pub-id><pub-id pub-id-type="pmid">16398892</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Duret</surname><given-names>C</given-names></name><name><surname>Wheeler</surname><given-names>S</given-names></name><name><surname>Marcus</surname><given-names>R</given-names></name><article-title>Once-weekly resistance exercise improves muscle strength and neuromuscular performance in older adults</article-title><source>J Am Geriatr Soc</source><year>1999</year><volume>47</volume><issue>10</issue><fpage>1208</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">10522954</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Myers</surname><given-names>AM</given-names></name><name><surname>Fletcher</surname><given-names>PC</given-names></name><name><surname>Myers</surname><given-names>AH</given-names></name><name><surname>Sherk</surname><given-names>W</given-names></name><article-title>Discriminative and evaluative properties of the activities-specific balance confidence (ABC) scale</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>1998</year><volume>53</volume><issue>4</issue><fpage>M287</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">18314568</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Henwood</surname><given-names>TR</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Lang</surname><given-names>TF</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><article-title>Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults</article-title><source>Gerontology</source><year>2009</year><volume>55</volume><issue>2</issue><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1159/000182084</pub-id><pub-id pub-id-type="pmid">19060453</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Gandek</surname><given-names>B</given-names></name><article-title>Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><issue>11</issue><fpage>903</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(98)00081-X</pub-id><pub-id pub-id-type="pmid">9817107</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Broom</surname><given-names>R</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Clemons</surname><given-names>M</given-names></name><name><surname>Eton</surname><given-names>D</given-names></name><name><surname>Dranitsaris</surname><given-names>G</given-names></name><name><surname>Simmons</surname><given-names>C</given-names></name><name><surname>Ooi</surname><given-names>W</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><article-title>Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the functional assessment of cancer therapy-bone pain</article-title><source>J Pain Symptom Manage</source><year>2009</year><volume>38</volume><issue>2</issue><fpage>244</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2008.08.005</pub-id><pub-id pub-id-type="pmid">19364633</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Sayers</surname><given-names>SP</given-names></name><name><surname>Jette</surname><given-names>AM</given-names></name><name><surname>Haley</surname><given-names>SM</given-names></name><name><surname>Heeren</surname><given-names>TC</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Fielding</surname><given-names>RA</given-names></name><article-title></article-title><source>J Am Geriatr Soc</source><year>2004</year><volume>52</volume><issue>9</issue><fpage>1554</fpage><lpage>1559</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2004.52422.x</pub-id><pub-id pub-id-type="pmid">15341561</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Chambers</surname><given-names>SK</given-names></name><name><surname>Lynch</surname><given-names>BM</given-names></name><name><surname>Aitken</surname><given-names>J</given-names></name><name><surname>Baade</surname><given-names>P</given-names></name><article-title>Relationship over time between psychological distress and physical activity in colorectal cancer survivors</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>10</issue><fpage>1600</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.5157</pub-id><pub-id pub-id-type="pmid">19255326</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Roth</surname><given-names>AJ</given-names></name><name><surname>Rosenfeld</surname><given-names>B</given-names></name><name><surname>Kornblith</surname><given-names>AB</given-names></name><name><surname>Gibson</surname><given-names>C</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Curley-Smart</surname><given-names>T</given-names></name><name><surname>Holland</surname><given-names>JC</given-names></name><name><surname>Breitbart</surname><given-names>W</given-names></name><article-title>The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer</article-title><source>Cancer</source><year>2003</year><volume>97</volume><issue>11</issue><fpage>2910</fpage><lpage>2918</lpage><pub-id pub-id-type="doi">10.1002/cncr.11386</pub-id><pub-id pub-id-type="pmid">12767107</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Sundin</surname><given-names>EC</given-names></name><name><surname>Horowitz</surname><given-names>MJ</given-names></name><article-title>Impact of event scale: psychometric properties</article-title><source>Br J Psychiatry</source><year>2002</year><volume>180</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1192/bjp.180.3.205</pub-id><pub-id pub-id-type="pmid">11872511</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Reddy</surname><given-names>S</given-names></name><name><surname>Bruera</surname><given-names>E</given-names></name><name><surname>Pace</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Reyes-Gibby</surname><given-names>CC</given-names></name><article-title>Clinically important improvement in the intensity of fatigue in patients with advanced cancer</article-title><source>J Palliat Med</source><year>2007</year><volume>10</volume><issue>5</issue><fpage>1068</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1089/jpm.2007.0007</pub-id><pub-id pub-id-type="pmid">17985963</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Cramp</surname><given-names>F</given-names></name><name><surname>Daniel</surname><given-names>J</given-names></name><article-title>Exercise for the management of cancer-related fatigue in adults</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><volume>16</volume><issue>2</issue><fpage>CD006145</fpage></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Beck</surname><given-names>SL</given-names></name><name><surname>Schwartz</surname><given-names>AL</given-names></name><name><surname>Towsley</surname><given-names>G</given-names></name><name><surname>Dudley</surname><given-names>W</given-names></name><name><surname>Barsevick</surname><given-names>A</given-names></name><article-title>Psychometric evaluation of the Pittsburgh sleep quality index in cancer patients</article-title><source>J Pain Symptom Manage</source><year>2004</year><volume>27</volume><issue>2</issue><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2003.12.002</pub-id><pub-id pub-id-type="pmid">15157038</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Buysse</surname><given-names>DJ</given-names></name><name><surname>Reynolds</surname><given-names>CF</given-names></name><name><surname>Monk</surname><given-names>TH</given-names></name><name><surname>Berman</surname><given-names>SR</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name><article-title>The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research</article-title><source>Psychiatry Res</source><year>1989</year><volume>28</volume><issue>2</issue><fpage>193</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/0165-1781(89)90047-4</pub-id><pub-id pub-id-type="pmid">2748771</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Ajzen</surname><given-names>I</given-names></name><article-title>The theory of planned behavior</article-title><source>Orgn Behav Hum Dec Processes</source><year>1991</year><volume>50</volume><fpage>179</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/0749-5978(91)90020-T</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Plasqui</surname><given-names>G</given-names></name><name><surname>Westerterp</surname><given-names>KR</given-names></name><article-title>Physical activity assessment with accelerometers: an evaluation against doubly labeled water</article-title><source>Obesity (Silver Spring)</source><year>2007</year><volume>15</volume><issue>10</issue><fpage>2371</fpage><lpage>2379</lpage><pub-id pub-id-type="doi">10.1038/oby.2007.281</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Spry</surname><given-names>N</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Denham</surname><given-names>J</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Lamb</surname><given-names>DS</given-names></name><name><surname>Levin</surname><given-names>G</given-names></name><name><surname>Duchesne</surname><given-names>G</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><article-title>A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial</article-title><source>BMC Cancer</source><year>2009</year><volume>9</volume><issue>1</issue><fpage>419</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-9-419</pub-id><pub-id pub-id-type="pmid">19951446</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Newton</surname><given-names>RU</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Spry</surname><given-names>N</given-names></name><name><surname>Gardiner</surname><given-names>RA</given-names></name><name><surname>Levin</surname><given-names>G</given-names></name><name><surname>Wall</surname><given-names>B</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Chambers</surname><given-names>SK</given-names></name><name><surname>Galvao</surname><given-names>DA</given-names></name><article-title>A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer</article-title><source>BMC Cancer</source><year>2009</year><volume>9</volume><fpage>210</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-9-210</pub-id><pub-id pub-id-type="pmid">19563641</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Spry</surname><given-names>N</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><article-title>Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response</article-title><source>J Urol</source><year>2011</year><volume>186</volume><issue>4</issue><fpage>1291</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2011.05.055</pub-id><pub-id pub-id-type="pmid">21849187</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Newton</surname><given-names>RU</given-names></name><name><surname>Hakkinen</surname><given-names>K</given-names></name><name><surname>Hakkinen</surname><given-names>A</given-names></name><name><surname>McCormick</surname><given-names>M</given-names></name><name><surname>Volek</surname><given-names>J</given-names></name><name><surname>Kraemer</surname><given-names>WJ</given-names></name><article-title>Mixed-methods resistance training increases power and strength of young and older men</article-title><source>Med Sci Sports Exerc</source><year>2002</year><volume>34</volume><issue>8</issue><fpage>1367</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.1097/00005768-200208000-00020</pub-id><pub-id pub-id-type="pmid">12165694</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><article-title>Review of exercise intervention studies in cancer patients</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>4</issue><fpage>899</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.06.085</pub-id><pub-id pub-id-type="pmid">15681536</pub-id></mixed-citation></ref></ref-list></back></article>